Tuis4DX • ASX
add
4DMedical Ltd
Vorige sluiting
$0,50
Dagwisseling
$0,53 - $0,56
Jaarwisseling
$0,41 - $0,83
Markkapitalisasie
217,02 m AUD
Gemiddelde volume
953,90 k
P/V-verhouding
-
Dividend-opbrengs
-
Primêre beurs
ASX
In die nuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
(AUD) | Jun. 2024info | J/J-verandering |
---|---|---|
Inkomste | 1,48 m | 1 172,70% |
Bedryfskoste | 12,56 m | 11,42% |
Netto inkomste | -10,19 m | -33,78% |
Netto winsgrens | -687,84 | 89,49% |
Wins per aandeel | — | — |
EBITDA | -11,09 m | -5,51% |
Effektiewe belastingkoers | -0,01% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
(AUD) | Jun. 2024info | J/J-verandering |
---|---|---|
Kontant en korttermynbeleggings | 30,61 m | -56,01% |
Totale bates | 120,02 m | 29,16% |
Totale aanspreeklikheid | 49,09 m | 128,71% |
Totale ekwiteit | 70,93 m | — |
Uitstaande aandele | 410,53 m | — |
Prys om te bespreek | 2,91 | — |
Opbrengs op bates | -23,28% | — |
Opbrengs op kapitaal | -36,73% | — |
Kontantvloei
Netto kontantverandering
(AUD) | Jun. 2024info | J/J-verandering |
---|---|---|
Netto inkomste | -10,19 m | -33,78% |
Kontant van bedrywe | -8,06 m | 8,54% |
Kontant van beleggings | -339,48 k | -21,29% |
Kontant van finansiering | -233,98 k | -101,11% |
Netto kontantverandering | -8,64 m | -172,48% |
Beskikbare kontantvloei | -5,43 m | 13,25% |
Meer oor
4DMedical is a medical technology company, based in Australia and the United States.
4DMedical created X-ray Velocimetry Lung Ventilation Analysis Software based on the company's proprietary XV Technology. XV Technology uses patented algorithms adapted from advanced aerodynamics research to process and enhance X-ray and Computed Tomography images. Airflow is measured throughout all regions of the lung, across all phases of the breath—providing clinicians with quantitative lung ventilation data in a report.
4DMedical has commercialized its XV Technology via a Software as a Service model, where patients are scanned using existing imaging equipment and analyzed by 4DMedical remotely. Airflow is measured throughout all regions of the lung, across all phases of the breath, delivering the capability to quantify regional lung function throughout the respiratory cycle, at every location within the lung. The lung function data is provided to clinicians and patients in a report that includes color-coded lung images. This approach enables the detection of subtle functional losses before lung structure is irreversibly effected by the disease. Wikipedia
Gestig
2013
Webwerf
Werknemers
145